Neuralgia News and Research

RSS
Neuralgia is pain in one or more nerves that occurs without stimulation of pain receptor (nociceptor) cells. Neuralgia pain is produced by a change in neurological structure or function rather than by the excitation of pain receptors that causes nociceptive pain.
Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Immune Pharmaceuticals closes underwriter's exercise of partial over-allotment option of 459,697 units

Calchan, Galapagos partner to discover and develop novel target for osteoarthritic pain

Calchan, Galapagos partner to discover and develop novel target for osteoarthritic pain

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Immune begins bertilimumab Phase II clinical trial for treatment of ulcerative colitis

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Researchers determine safety and effectiveness of neurostimulation to treat chronic pain

Researchers determine safety and effectiveness of neurostimulation to treat chronic pain

SCILEX completes patient enrollment to study Ztlido for treatment of postherpetic neuralgia

SCILEX completes patient enrollment to study Ztlido for treatment of postherpetic neuralgia

Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

Lyfebulb, Immune collaborate to increase awareness of bullous pemphigoid

AMS agrees to sell Gamma Knife and radiation therapy services business in Turkey to Euromedic

AMS agrees to sell Gamma Knife and radiation therapy services business in Turkey to Euromedic

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

Acorda gets FDA Complete Response Letter for PLUMIAZ Nasal Spray NDA

TWi and Endo Pharmaceuticals settle patent litigation over Lidoderm product

TWi and Endo Pharmaceuticals settle patent litigation over Lidoderm product

AMS' revenues decrease 4.6% to $3,937,000 in fourth quarter 2013

AMS' revenues decrease 4.6% to $3,937,000 in fourth quarter 2013

Treating long wait-times dictate long-term success of spinal cord stimulation therapy

Treating long wait-times dictate long-term success of spinal cord stimulation therapy

Loyola physician sheds light on common and painful viral infection, shingles

Loyola physician sheds light on common and painful viral infection, shingles

New Gamma Knife stereotactic radiosurgery reduces severe facial pain caused by nerve disorder

New Gamma Knife stereotactic radiosurgery reduces severe facial pain caused by nerve disorder

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

Spinifex announces results of Phase 2 clinical trial of EMA401 in postherpetic neuralgia

New drug treatment effective against chronic pain caused by nerve damage post shingles

New drug treatment effective against chronic pain caused by nerve damage post shingles

Patient's EMR coupled with pharmacist intervention improves preventative care of shingles

Patient's EMR coupled with pharmacist intervention improves preventative care of shingles

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Zalicus announces top-line results from Z160 Phase 2 clinical studies in chronic pain indications

Depomed reports financial results for third quarter 2013

Depomed reports financial results for third quarter 2013

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules

Pfizer announces top-line results from phase 3b studies with Lyrica Capsules